Navignostics has won second place in the DxPx Business Plan Competition at the DxPx Europe Conference in Munich, competing against leading diagnostic innovators for up to $2 million in convertible loan funding.
The company’s spatial single-cell proteomics technology enables detailed analysis of tumour and immune cells directly within tissue samples, allowing clinicians to understand cancer cell composition, interactions, and resistance mechanisms to guide personalized therapy decisions for late-stage cancer patients.
Navignostics was among eight finalists presenting to a panel of over 30 venture capital firms. The cohort – ADmit Therapeutics, MyImmune, Noscendo, Proteins.1, FLASH Tissue Diagnostics, Virtuosis AI, Navignostics, and DermR Health – represented bold ideas and strong science shaping the future of diagnostics and biotools.
This follows Navignostics’ Swiss Tech Award 2025 win and groundbreaking Nature Medicine publication demonstrating threefold improvement in disease control for heavily pretreated melanoma patients.
About the DxPx Conference
DxPx Europe is an annual partnering conference connecting diagnostic innovators with investors and industry leaders. The Business Plan Competition showcases emerging companies to venture capital firms, offering funding opportunities and strategic partnerships in diagnostics, precision medicine, and life science tools.
